17 articles
The next obesity drugs, and what their trials showed
Several drugs behind semaglutide and tirzepatide have phase 2 or phase 3 results, and one oral pill is now approved. Some of the rest are already sold online as research chemicals years before any approval. These articles report what each trial measured and found, separate peer-reviewed results from company announcements, and say which ones you can lawfully get today.
Retatrutide: What the Evidence Actually Shows
TRIUMPH-1 is now peer-reviewed: 25.0% at 80 weeks counting everyone randomized, against 28.3% in Lilly's release for the same trial. The drug is approved nowhere, and Lilly has not yet filed.
8 min read · 10 citationsRetatrutide Price and Release Date: What Is Known
Retatrutide has no legal price and no release date. Lilly plans to file for U.S. approval in Q1 2027. What is sold online now is illegal, and FDA has sent warning letters to at least 21 companies selling it.
8 min read · 12 citationsRetatrutide's Phase 3, and the Gray Market
A triple-receptor agonist cut HbA1c 1.94 points and weight 15.3% in a phase 3 trial. It is approved nowhere, and six sellers in our register are already shipping something by that name.
8 min read · 3 citationsCagrilintide: What the Evidence Shows, and Why You Can't Buy It
Cagrilintide, Novo Nordisk's amylin analog, produced 11.8% weight loss on its own at 68 weeks, less than semaglutide. It is not approved, cannot be compounded, and FDA has warned companies selling it.
9 min read · 16 citationsEloralintide and Petrelintide: The Amylin-Only Drugs in Phase 3
In phase 2, Lilly's eloralintide cut weight by about 20% at 48 weeks; Zealand and Roche's petrelintide up to 10.7% at 42 weeks with little vomiting. Both are in phase 3, due to finish in 2028. Neither is approved.
10 min read · 26 citationsAmycretin: A 24% Weight Figure, and the Trial It Came From
Once-weekly amycretin produced an estimated 24.3% bodyweight reduction at 36 weeks against 1.1% on placebo. It came from a single-site phase 1b/2a study of 125 people whose primary endpoint was counting adverse events.
5 min read · 4 citationsSurvodutide: What the Phase 3 Evidence Shows
Survodutide, Boehringer Ingelheim's glucagon/GLP-1 dual agonist, cut weight 12.2% to 13.0% at 76 weeks in phase 3, less in type 2 diabetes. About one in five stopped over gut side effects. It is not approved and has no filing date.
9 min read · 15 citationsMariTide (Maridebart Cafraglutide): What the Evidence Shows
Amgen's monthly MariTide cut weight 12.3% to 16.2% at 52 weeks in phase 2, against 2.5% on placebo. It blocks GIP where tirzepatide activates it. Side effects, the MARITIME phase 3 trials, and why it cannot be bought yet.
10 min read · 13 citationsFoundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule
Approved April 1, 2026, as the second GLP-1 tablet for weight management, and the only one taken with or without food. It produced 11.1% weight loss at 72 weeks, below both injectable rivals. The label, the trials and the interactions.
9 min read · 11 citationsElecoglipron: A Second Oral GLP-1 Pill in Phase 2
Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.
5 min read · 1 citationPemvidutide: What the Evidence Shows
Pemvidutide, Altimmune's GLP-1/glucagon dual agonist, resolved MASH in 52% to 58% of patients at 24 weeks in a Lancet trial but missed on scarring. Its obesity and lean-mass results are company-reported only, and its phase 3 is in liver disease.
10 min read · 25 citationsHow to Join a GLP-1 Clinical Trial: Finding a Real Obesity Drug Study
How to find a recruiting obesity-drug trial on ClinicalTrials.gov, who qualifies, your odds of placebo, what trials pay under FDA rules, your consent rights, why the drug usually stops when the trial ends, and how to spot fake trials.
12 min read · 26 citationsTesofensine for Weight Loss: What the Trials Showed and Why It Isn't Approved
Tesofensine is an unapproved triple reuptake inhibitor pill. Its 2008 phase 2 trial showed 9.2% weight loss at 24 weeks on 0.5 mg, but carries a Lancet expression of concern. Heart rate, mood, the stalled Mexican filing, and how it compares with Wegovy and Zepbound.
11 min read · 29 citationsRetatrutide Side Effects: What the TRIUMPH Trials Report, Dose by Dose
Retatrutide's trial side effects were mostly nausea, diarrhea, constipation and vomiting, rising with dose, plus a skin sensation called dysesthesia and low blood pressure. Dropout rates by dose, heart rate, and why it is not yet known to be safe.
10 min read · 14 citationsRetatrutide Dosing: The Doses, Starting Dose and Escalation Used in the Trials
Retatrutide has no approved dose. Phase 3 trials started everyone at 2 mg weekly and stepped up every four weeks to 4, 9 or 12 mg. What each dose did to weight and dropout, why 12 mg added little over 9 mg, and why a vial's dosing chart is not a trial protocol.
11 min read · 16 citationsMazdutide: What the Trials Show, and Why It Is Approved Only in China
Mazdutide, the Innovent and Lilly GLP-1/glucagon dual agonist, is approved only in China. Phase 3 trials found 14.0% weight loss at 48 weeks on 6 mg and 16.7% at 60 weeks on 9 mg. Side effects rise with dose. It has no US phase 3 trial.
10 min read · 27 citationsWegovy Pill vs Injection: Is the Pill as Good as the Shot?
The Wegovy pill cut weight 13.6% in its trial and the shot 14.9% in its own, and an indirect comparison could not tell them apart. What differs: the daily fasting rule, the dose steps, side effects, the 7.2 mg pen and about $50 a month.
10 min read · 6 citations